Precision Partners With Tiziana for the Use of Foralumab as a Novel Lymphodepletion Agent; How Could an Anti-CD3 Antibody Improve CAR-T Efficacy? TCR2 Tx’s Gavo-cel Receives Orphan Drug Designation
On Thursday, September 2, Precision BioSciences announced (press release) an exclusive license agreement with Tiziana to evaluate foralumab (anti-CD3 monoclonal antibody) as a lymphodepletion (LD) agent for their allogeneic CAR-T therapies. On the same day, TCR2 Tx reported (press release) that the FDA has granted gavo-cel (mesothelin-targeted TRuC-T) Orphan Drug Designation (ODD) for the treatment of cholangiocarcinoma. Below, Celltelligence provides insights on how a foralumab LD regimen could enhance allogeneic CAR-T efficacy, while discussing gavo-cel’s ODD in cholangiocarcinoma.